SCHEMBL684356

SCHEMBL684356

Cn1c(=O)c2c(ncn2CN2CCN(c3ccccc3Cl)CC2)n(C)c1=O

nearest known ligand 0.58

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
HTR7 P34969 1/20 0.58
HTR6 P50406 1/20 0.58
TSHR P16473 2/20 0.56
ADORA2B P29275 6/20 0.56
SMN1; SMN2 Q16637 3/20 0.56
RXFP1 Q9HBX9 3/20 0.56
L3MBTL1 Q9Y468 3/20 0.55
LMNA P02545 2/20 0.52
MAPK1 P28482 2/20 0.52
ALDH1A1 P00352 1/20 0.52
MAPT P10636 1/20 0.51
HTT P42858 2/20 0.51
UBE2N P61088 2/20 0.51
GLA P06280 1/20 0.50
TP53 P04637 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL458792 0.91 HTR7 (0.63) HTR7HTR6TSHRADORA2BSMN1; SMN2
SCHEMBL29375465 0.91 HTR7 (0.63) HTR7HTR6TSHRADORA2BSMN1; SMN2
Hydrochloric Acid SCHEMBL2290149 0.90 HTR7 (0.65) HTR7HTR6TSHRADORA2BSMN1; SMN2
Ammonia Solution, Strong SCHEMBL12804036 0.90 HTR7 (0.62) HTR7HTR6TSHRADORA2BSMN1; SMN2
SCHEMBL11152654 0.89 HTR7 (0.73) HTR7HTR6TSHRADORA2BSMN1; SMN2
SCHEMBL682810 0.89 HTR7 (0.58) HTR7HTR6TSHRADORA2BSMN1; SMN2
SCHEMBL11152582 0.89 HTR7 (0.74) HTR7HTR6TSHRADORA2BSMN1; SMN2
SCHEMBL682820 0.86 L3MBTL1 (0.73) HTR7HTR6TSHRL3MBTL1
SCHEMBL683655 0.85 HTR7 (0.77) HTR7HTR6TSHRADORA2BSMN1; SMN2
SCHEMBL682816 0.85 TSHR (0.55) HTR7HTR6TSHRADORA2BSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110269717-A1 NEUROGENESIS BY MODULATING ANGIOTENSIN BRAINCELLS INC. (US) 2011-11-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110269717-A1 NEUROGENESIS BY MODULATING ANGIOTENSIN NGF, DCX, BDNF HTR7 1398/4885HTR6 683/4885TSHR 1873/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.